(January 22, 2021, 10:44 AM EST) -- WILMINGTON, Del. — Amgen Inc., maker of the chronic heart failure (CHF) drug Corlanor, levied allegations of patent infringement against the filers of an abbreviated new drug application (ANDA) in a...
Generic Drug Application Yields Patent Complaint In Delaware Federal Court
To view the full article, register now.
Try for FREE for fourteen days
Already a subscriber? Click here to login